Cannabis for the Prophylactic Treatment of Migraine
ConditionChronic Migraine
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age25+
SponsorUniversity of Calgary
About this trial
This study will evaluate the efficacy and safety of cannabis for the treatment of chronic migraine headaches. Study subjects will be randomized to one of three groups: lower dose CBD, higher dose CBD or placebo.
Eligibility criteria
Qualifiers
Subject is willing and able to give signed informed consent.
Male and female patients aged 25 years or older.
History of migraine for at least 12 months as diagnosed by the International Classification of Headache Disorders (ICHD-3).
Chronic migraine for at least the previous 3 months prior to screening, as diagnosed by ICHD-3.
Disqualifiers
Other active primary headaches, such as cluster headache, hemicrania continua, etc.
Any secondary headache, such as headache related to intracranial hypertension, intracranial hypotension, hydrocephalus, intracranial mass lesion, etc.
Pregnant, planning to become pregnant, or breastfeeding.
Active or significant history of major mental illness, including severe depression, or anxiety, and any history of psychosis or schizophrenia.
Trial design
Treatments tested in this trial
- CBD 100 mg OD
- CBD 200 mg OD
- Placebo
Treatment groups
72 Participants
are divided into 3 treatment groupsLocations
1CHAMP Research (Calgary Headache Assessment & Management Program)T3M 1M4, CalgaryAlberta, Canada
Sponsors and collaborators
University of Calgary
Lead sponsor
Source ClinicalTrials.gov